Next Generation News and Research

RSS

Hydros-TA therapy provides next generation of osteoarthritis relief

Osteoarthritis (OA) is the most common form of arthritis, affecting roughly 10% of Canadians. This degradation of the joints is painful and crippling, especially when it affects the knee. Although there are viable OA treatment options, they are short-lived and can have serious side-effects.

10 Aug 2011

GE Healthcare receives FDA clearance for Optima CT660 system

GE Healthcare today announced FDA clearance of Optima CT660 - a powerful and compact Computed Tomography (CT) system offering improvements from its predecessors in diagnostic capabilities at low dose levels, and designed for sustainability and ease-of-use.

9 Aug 2011

Affymetrix announces commercialization of next-generation human transcriptome array

Affymetrix, Inc. today announced commercialization of the next-generation human transcriptome array demonstrated by Stanford University researchers to be superior to mRNA sequencing (RNA-Seq) in gene expression profiling studies.

8 Aug 2011

Clinical warning system that uses wireless sensors can track vital signs of at-risk patients

A clinical warning system that uses wireless sensors to track the vital signs of at-risk patients is undergoing a feasibility study at Barnes-Jewish Hospital in St. Louis.

5 Aug 2011

Study stresses importance of broad-spectrum sunscreen to help prevent skin cancer

With so many sunscreen options on the market, it can be confusing to know which ones offer the best protection. A new study further emphasizes the importance of selecting a broad-spectrum sunscreen to protect the skin against skin cancer and early aging.

5 Aug 2011

Micromet second quarter total revenues increase to $7.1 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

Columbia Laboratories second quarter total net revenues increase to $19.2 million

Columbia Laboratories, Inc. today reported financial results for the three- and six-month periods ended June 30, 2011.

4 Aug 2011

Bad teeth in Ozzie kids worries dental health experts

According dental health experts, changes in diet, un-flouridated bottled water and the habit of “constantly bathing” ones teeth in sugary drinks is to blame for the rising number of decaying and rotten teeth found in children

4 Aug 2011

IDC Health Insights survey ranks Accenture as top life science IT services vendor

Accenture has been ranked as the number one life science information technology (IT) services vendor in a survey conducted by IDC Health Insights.

3 Aug 2011

Illumina and University of Oxford collaborate to sequence whole genomes

Illumina, Inc. today announced it will collaborate with the University of Oxford to sequence the whole genomes of 500 individuals afflicted with a range of life-threatening diseases that pose major challenges in diagnosis, treatment, and care. Illumina HiSeq™ 2000 systems will be used to generate sequence data for the 500 genomes.

From Illumina, Inc. 3 Aug 2011

SIS receives U.S. patent for 3D SNAPSHOT

Spatial Integrated Systems, Inc., a leader in the development and integration of solutions incorporating next generation digital 3D data capture and processing technologies, announced today that it has been awarded U.S. patent 7,986,321 for a system and method for generating structured light for three-dimensional image rendering.

3 Aug 2011

Zalicus second quarter revenue decreases to $1.8 million

Zalicus Inc. today reported financial results for the second quarter ended June 30, 2011.

3 Aug 2011

UC San Diego Health System named 'Most Wired' for sixth consecutive year

For the sixth consecutive year, UC San Diego Health System was named one of the nation's "Most Wired" by Hospitals and Health Networks, a publication of the American Hospital Association.

3 Aug 2011

Cancer Research UK honors Nottingham scientist with prestigious award

A University of Nottingham scientist who uses fruit flies to study the genetics of cancer has won a prestigious award from Cancer Research UK.

3 Aug 2011

AtriCure second quarter revenue increases 18.2% to $16.8 million

AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced financial results for the second quarter of 2011. Revenue was $16.8 million, reflecting 18.2 percent growth over the second quarter of 2010.

2 Aug 2011

MindFrame receives CE mark approval for Capture LP and Flow LP devices

MindFrame Inc. today announces receiving CE mark approval for the MindFrame Capture LP™ and MindFrame Flow LP™ devices. Part of the comprehensive portfolio of MindFrame Therapy Solutions™, these low profile devices can be deployed through a smaller microcatheter to improve access through tortuous vessel anatomies.

2 Aug 2011

Nature Biotechnology publishes BGI, GT Life Sciences' study on CHO K1 genome

BGI, the world's largest genomics organization, and GT Life Sciences, Inc., a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, announced today that their collaborative study on the genomic sequence of the Chinese hamster ovary (CHO) K1 cell line was published July 31, 2011 online in Nature Biotechnology.

1 Aug 2011

Electrochem launches new company website and corporate brand

Electrochem Solutions, Inc. announced today the launch of its rebranded and redesigned company website.

1 Aug 2011

Skin cancer vaccine on the way: Cancer expert Prof Ian Frazer

In a major medical breakthrough, cancer expert Prof Ian Frazer is on the verge of developing a vaccine against skin cancer within a year. The former ‘Australian of the Year’ and creator of the world's first cervical cancer vaccine, Gardasil, has developed a world-first strategy to combat the insidious disease that affects two out of three Australians.

31 Jul 2011

CDC, ZKBS classifies Advaxis Agents as non-pathogenic materials

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has received affirmation by the Public Health Service of the U. S. Centers for Disease Control and Prevention and the Zentrale Kommission für die Biologische Sicherheit, the Central Commission for Biological Safety in Germany, that Advaxis strains, constructs and immunotherapies have been attenuated to the point that they are classified as non-pathogenic materials for handling and shipment.

30 Jul 2011